Dr. Bach’s Drug Pricing Lab (DPL) is based at Memorial Sloan Kettering Cancer Center. The DPL focuses on the development of rational approaches to drug pricing and health insurance coverage that sustain innovation while ensuring patient access and affordability. The DPL focuses its efforts on four major work streams:

  1. Research on the current state of U.S. drug pricing and its effects
  2. Development of solutions to align drug prices with value
  3. Pilot programs to test solutions in real world settings
  4. Evidence-based and unbiased resources for policy makers

The DPL conducts non-partisan, independent academic research, which is made publicly available. All views expressed are our own, and do not represent the views of Memorial Sloan Kettering Cancer Center. The DPL receives funding from the Laura and John Arnold Foundation and Kaiser Permanente.


Dr. Peter B. Bach

Director of Memorial Sloan Kettering's Center for Health Policy and Outcomes

Peter B. Bach, Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients

Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8,500 each year.

In 2012, he and other physicians at MSK drew attention to the high price of a newly approved cancer drug and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer.

Dr. Bach’s work in lung cancer screening has led to the development of several lung cancer screening guidelines and one of the first-ever risk-prediction models for this disease. He has also proposed a number of strategies for Medicare to link payment to the value of healthcare services delivered.

Dr. Bach has been inducted into the National Academy of Medicine, American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006.

Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 MinutesView a comprehensive list of media coverage of Dr. Bach and his work.

Dr. Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. Dr. Bach has been a faculty member in MSK’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008.

Disclosures for the past 3 years:

Speaking fees (2018) United Rheumatology, American Osteopathic Association, National Institute for Health Care Management | (2017) ASHP, Gilead, WebMD, Baylor Medical School, HDArsrch Foundation, Goldman Sachs, Academy of Physicians in Clinical Research, Politico, Mayo-Transform Conference, Defined Health, Ohio State University, Vizient, JMP Securities | (2016) Anthem, Excellus Health Plan, University of Miami, Dartmouth College, AMA, NYU, Brown University, Hematology Oncology Pharmacy Associates, Northwestern University, University of Texas Health Sciences, Booz Allen, Novartis, American Enterprise Institute, Janssen, Third Rock Ventures, Cummins Physician Board

Consulting (2018) Foundation Medicine, Grail | (2017) Foundation Medicine | (2016) Foundation Medicine, Examworks | (2015) Foundation Medicine, Examworks

Anna Kaltenboeck

Senior Health Economist and Program Director

Ms. Kaltenboeck is a senior health economist and the program director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. Her work focuses on the development and application of value-based pricing methods, as well as policies that foster rational and sustainable drug pricing.

Prior to joining MSKCC, Ms. Kaltenboeck spent 10 years consulting on health economics and outcomes research, as well as pricing and market access for pharmaceutical and diagnostic products. An alumna of both Analysis Group and IMS Consulting Group, the scope of her work spans the US, EU5, and emerging economies. She has published numerous articles in peer-reviewed scientific and policy journals.

Ms. Kaltenboeck holds bachelor’s and master’s degrees in economics from Tufts University.


Speaking fees: (2018) AstraZeneca


Jennifer C. Chen

Project Portfolio Manager

Ms. Chen is a project portfolio manager at the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. She oversees day-to-day operations of program grants.

Ms. Chen holds an MPH in epidemiology and pharmaceuticals management from Boston University School of Public Health, and a BS in anthropology from the University of California, Riverside.

Jennifer Ohn

Research Data Analyst

Ms. Ohn is a research data analyst at the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. Her work primarily involves tracking drug pricing policy proposals, drug pricing data analyses, and value-based pricing pilots.

Ms. Ohn holds an MPH in policy and management from New York University and a BS in neuroscience from Bucknell University.

Susan Chimonas

Qualitative Research Consultant

Dr. Chimonas is a sociologist in the Health Policy and Outcomes Group at Memorial Sloan Kettering Cancer Center.  She is a national expert on issues of conflict of interest and transparency in medicine, and she has over 20 years of experience in qualitative and mixed methods research.  Her methodological expertise includes conducting and analyzing interviews, focus groups, usability tests, surveys, case studies, policy analysis, and other approaches.

After graduating summa cum laude from Dartmouth College, Dr. Chimonas received her PhD in sociology from the University of Michigan.

Michael Curry

Assistant Research Biostatistician

Mr. Curry is a biostatistician in the Health Outcomes Group at Memorial Sloan Kettering Cancer Center. He collaborates with physicians and completes statistical analyses for studies involving large observational databases such as the NCI’s Surveillance and Epidemiology End Results Program (SEER) registry linked to Medicare data. Studies are generally focused on describing real-world trends in cancer care, drug pricing, and comparing outcomes among cancer treatments.

Mr. Curry holds an MA in experimental psychology from Radford University, an MS in biostatistics and epidemiology from Northwestern University, and a BA in psychology from SUNY Cortland.

Nancy Yu

Financial and Biopharma Industry Analyst

Ms. Yu is a financial and biopharma industry analyst in the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center.  Her work focuses on financial and policy analyses that support the value and accessibility of prescription drugs.

Prior to joining MSKCC, Ms. Yu spent over ten years working in the healthcare investment industry, eight of which was in the equity research department at Morgan Stanley.  In addition to her time as a sell-side analyst, Ms. Yu was the global pharmaceuticals analyst for a hedge fund and served as chief operating officer for a start-up healthcare investment firm.

Ms. Yu holds both an MBA and a master’s degree in asian studies from the University of Michigan, and an AB from Duke University.